Topotecan plus cyclophosphamide in adults with relapsed or refractory pediatric-type sarcoma: a retrospective analysis from the German Sarcoma Medical Oncology Group (AIO)
| Autor: | E. Papesch, V. Grünwald, Rolf D. Issels, Bernd Hertenstein, I. Sturm, Jörg T. Hartmann, K. San Nicolo, Stefan W. Krause |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Oncology
Adult Male medicine.medical_specialty Cyclophosphamide Adolescent medicine.medical_treatment Young Adult Refractory Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Pharmacology (medical) Retrospective Studies Pharmacology Chemotherapy business.industry Induction chemotherapy Sarcoma Middle Aged medicine.disease Prognosis Survival Analysis Regimen Topotecan Female Neoplasm Recurrence Local business Progressive disease medicine.drug |
| Zdroj: | Investigational new drugs. 33(5) |
| ISSN: | 1573-0646 |
| Popis: | Background To assess the efficacy and safety of topotecan and cyclophosphamide (TC) in adult patients with pediatric-type sarcoma subtypes who failed induction chemotherapy. Patients and methods Patients with pediatric sarcoma subtypes, refractory to or relapsed after at least one prior induction chemotherapy, inoperable, ECOG PS 0-2, with measurable, progressive disease (PD), adequate organ functions, who have been treated with TC combination were retrospectively analysed within the AIO and SAREZ/BMBF network. Results Thirty-nine patients, median age 28 years (18–58), 14 females, 25 males, have been identified. All patients had received induction treatment according to (inter)national study protocols. Second-line TC was applied in 33 patients (≥3rd-line in 6 patients). Twenty-three patients had refractory disease (evidence of PD during induction chemotherapy); 8 patients experienced an early relapse within 6 months as well as 8 patients after more than 24 months (late relapse). A median of 3 cycles (range, 1–6) had been applied and antitumor activity was: CR 2.6 %, PR 7.9 %, and disease stabilisation (SD) 26.3 %. PR lasted 32.8 months and median duration in patients with SD was 5 months (range, 2.0–14.7). The 3/6-months progression-free rates were 43.2 and 18.9 %. Conclusions Limited activity was seen in adult pts with refractory or relapsed pediatric-type sarcomas with the regimen which has proven activity in pediatric patients. Adults with refractory small cell sarcoma appear to have a similar dismal outcome as seen in pts with common adult-type histologies; however, a subset of patients has achieved long-lasting remissions on TC resulting in long-term survival. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink